Imunon (IMNN)

• Market cap: $12.8M
• 1 day: -0.61%
• 5 days: -1.39%
• 1 month: -2.49%
• 3 months: 3.92%
• 6 months: -15.62%
• Year to date: -16.42%
• 1 year: 0.76%
• 5 years: -93.07%
• 10 years: -99.84%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Employees: 25

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

0% more funds holding

Funds holding: 22 [Q3] → 22 (+0) [Q4]

4.12% less ownership

Funds ownership: 7.06% [Q3] → 2.93% (-4.12%) [Q4]

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

63% less capital invested

Capital invested by funds: $1.08M [Q3] → $404K (-$673K) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 1,267% upside
• Avg. target: $21 2,236% upside
• High target: $29 3,204% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 26% 1-year accuracy 72 / 279 met price target	3,204% upside $29	Buy Maintained	27 Feb 2025
HC Wainwright & Co. Emily Bodnar 18% 1-year accuracy 28 / 157 met price target	1,267% upside $12	Buy Reiterated	19 Dec 2024